SITAGLIPTIN S.K. 100 MG

Pajjiż: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

SITAGLIPTIN AS HYDROCHLORIDE MONOHYDRATE

Disponibbli minn:

K.S.KIM INTERNATIONAL (SK- PHARMA) LTD., ISRAEL

Kodiċi ATC:

A10BH01

Għamla farmaċewtika:

FILM COATED TABLETS

Kompożizzjoni:

SITAGLIPTIN AS HYDROCHLORIDE MONOHYDRATE 100 MG

Rotta amministrattiva:

PER OS

Tip ta 'preskrizzjoni:

Required

Manifatturat minn:

HETERO LABS LIMITED, INDIA

Żona terapewtika:

SITAGLIPTIN

Indikazzjonijiet terapewtiċi:

Sitagliptin S.K. is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. Important limitations of use: Sitagliptin S.K. should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings. Sitagliptin S.K. has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Sitagliptin S.K..

Data ta 'l-awtorizzazzjoni:

2023-02-12

Fuljett ta 'informazzjoni

PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS'
REGULATIONS (PREPARATIONS) – 1986
This medicine is marketed upon physician's prescription only
SITAGLIPTIN S.K. 25 MG
Film-coated tablets
EACH FILM-COATED TABLET CONTAINS:
Sitagliptin (as hydrochloride monohydrate) 25 mg
SITAGLIPTIN S.K.50 MG
Film-coated tablets
EACH FILM-COATED TABLET CONTAINS:
Sitagliptin (as hydrochloride monohydrate) 50 mg
SITAGLIPTIN S.K. 100 MG
Film-coated tablets
Sitagliptin (as hydrochloride monohydrate) 100 mg
For a list of inactive ingredients please refer to section 6
“FURTHER INFORMATION”. See also section 2.8
“Important information about some of the ingredients of the
medicine”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THIS MEDICINE.
•
This leaflet contains concise information about Sitagliptin S.K.. If
you have any further questions,
refer to the doctor or pharmacist
•
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even if it
seems to you that their ailment is similar
•
This medicine is not intended for administration to children and
adolescents under 18 years of age
1. WHAT SITAGLIPTIN S.K.
IS INTENDED FOR?
Sitagliptin S.K.
is indicated as an adjunct to diet and exercise, to improve glycemic
control in adults with type 2
diabetes mellitus.
IMPORTANT LIMITATIONS OF USE:
Sitagliptin S.K.
should not be used in patients with type 1 diabetes or for the
treatment of diabetic
ketoacidosis, as it would not be effective in these settings.
Sitagliptin S.K.
has not been studied in patients with a history of pancreatitis. It is
unknown whether
patients with a history of pancreatitis are at increased risk for the
development of pancreatitis while using
Sitagliptin S.K.
.
THERAPEUTIC GROUP
:
DPP-4 enzyme inhibitors.
Sitagliptin S.K.
is a member of a class of medicines you take by mouth called DPP-4
inhibitors
(dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in
adult patients with type 2 diabetes
mellitus.
2. BEFORE USING SITAGLIPTIN S.K.
2.1 DO NOT USE SIT